The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes that the Annual General Meeting 2018 elects Jan Ståhlberg as new member and Chairman of the Board, as Stanley Brodén who has been the Chairman of the Board since 2015 has declined reelection.
Jan Ståhlberg is Vice Chairman of EQT AB and has been active in EQT since 1995. Earlier in his career, between 1985 and 1994, Jan Ståhlberg worked in various positions at Ovako Steel.
Jan Ståhlberg has extensive experience in board work, both domestically and internationally, including the cancer diagnostic company Dako, Carl Zeiss Vision and Gambro in the life science industry.
Jan Ståhlberg holds a BSc from the Stockholm School of Economics and has studied in the MBA program at the New York University Stern School of Business.
At year-end 2017, Jan Ståhlberg had a total of 1 584 786 B shares in Bactiguard, corresponding to 4.8 percent of the capital and 2.3 percent of the votes, which means that he was the third largest shareholder in the company at the time.
The Nomination Committee’s full proposal will be presented in the notice convening the Annual General Meeting 2018 and on the company’s website at the same time.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2018-01-22, at. 08.00
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
